Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 12Esophageal Neoplasms 9Esophageal Squamous Cell Carcinoma 8Squamous Cell Carcinoma of Head and Neck 7Uterine Cervical Neoplasms 6Pancreatic Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Recurrence 2Pancreatic cancer, adult 2Lung Neoplasms 2Diffuse Intrinsic Pontine Glioma 2Uterine Cervical Dysplasia 1Squamous Cell Carcinoma of Anal Canal 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Locally Advanced Rectal Cancer 1Hypopharyngeal Neoplasms 1HCC 1Glioma 1Glioblastoma 1Esophageal 1Colorectal Neoplasms 1Childhood Brain Stem Neoplasm 1

Interventions

Temozolomide 6Capecitabine 4Everolimus 3Thalidomide 2Sunitinib 2Streptozocin 2Octreotide 2Injections 2Fluorouracil 2surufatinib 1sargramostim 1recombinant interferon alpha 2b-like protein 1nimotuzumab 1motesanib diphosphate 1montanide ISA 51 1lutetium Lu 177 dotatate 1incomplete Freund's adjuvant 1ibrutinib 1ganitumab 1cabozantinib 1belzutifan 1batifiban 1atezolizumab 1abemaciclib 1Tegafur 1Specimen Handling 1PM 01183 1Metformin 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenoma, Islet Cell × nimotuzumab × Clear all
NCT05316480 2022-04-07

Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

Fudan University

Phase 2 Not yet recruiting
42 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡